- Nivolumab (CAS 946414-94-4) is a high-purity pharmaceutical API classified as a PD-1 inhibitor, featuring a recombinant fully human IgG4 monoclonal antibody structure with high target affinity. It specifically binds to the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 ligands to restore the immune system’s ability to recognize and eliminate cancer cells. This premium API exhibits stable bioactivity and minimal immunogenicity, ensuring consistent performance in intravenous injectable formulations.
- It caters to the core needs of oncology drug manufacturers, biotech firms, and clinical research institutions. As a foundational immunotherapy agent, it is widely applied in developing treatments for non-small cell lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma. Produced under strict GMP-compliant biomanufacturing processes, each batch undergoes rigorous purity and potency testing to meet global biopharmaceutical standards. For businesses prioritizing innovative, broad-spectrum anticancer immunotherapies, this Nivolumab API serves as a critical raw material for advancing targeted cancer therapy research and clinical applications.
Nivolumab (CAS 946414-94-4) – Anti-PD-1 Monoclonal Antibody Anticancer API
$16,000.00
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication in the class of immune checkpoint inhibitors.
Be the first to review “Nivolumab (CAS 946414-94-4) – Anti-PD-1 Monoclonal Antibody Anticancer API”
Reviews
There are no reviews yet.